Hot Features
プレミアム
Allurion Technologies Inc (ALUR)
NYSE
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient ... Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts. 詳細を表示
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024...
19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on...
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S...
In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage decreased at six months with no change in muscle...
Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health Allurion Technologies, Inc. (NYSE: ALUR), a...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York...
In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today...
Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity...
Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program Separate studies with patients on GLP-1 therapy report significant weight...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0852 | -15.6906077348 | 0.543 | 0.5631 | 0.31 | 646829 | 0.39154497 | CS |
| 4 | -0.2422 | -34.6 | 0.7 | 0.8 | 0.31 | 278977 | 0.50430859 | CS |
| 12 | -0.3922 | -46.1411764706 | 0.85 | 0.8898 | 0.31 | 223949 | 0.58592889 | CS |
| 26 | -1.2322 | -72.9112426036 | 1.69 | 3.55 | 0.31 | 759443 | 2.05197936 | CS |
| 52 | -3.1622 | -87.3535911602 | 3.62 | 4.24 | 0.31 | 648632 | 2.44579073 | CS |
| 156 | -8.5422 | -94.9133333333 | 9 | 9 | 0.31 | 522234 | 2.57289637 | CS |
| 260 | -8.5422 | -94.9133333333 | 9 | 9 | 0.31 | 522234 | 2.57289637 | CS |
oleskool
1日前
PonkenPlonken
5日前
Invest-in-America
5月前
Penny chatter
5月前
Invest-in-America
5月前
Invest-in-America
5月前
glenn1919
5月前
Topgun21
5月前
Penny chatter
5月前
Invest-in-America
5月前
Penny chatter
5月前
Invest-in-America
5月前
Penny chatter
5月前
Invest-in-America
5月前
Penny chatter
5月前
Invest-in-America
5月前
Penny chatter
5月前
Invest-in-America
5月前
Penny chatter
5月前
Invest-in-America
5月前
Invest-in-America
5月前
Penny chatter
5月前
TrendTrade2016
5月前
Invest-in-America
5月前
Invest-in-America
5月前
Penny chatter
5月前
TrendTrade2016
5月前
Invest-in-America
5月前
Invest-in-America
5月前
glenn1919
5月前
TrendTrade2016
5月前
Invest-in-America
5月前
Monksdream
8月前
Monksdream
8月前
Monksdream
8月前
dinogreeves
8月前
dinogreeves
8月前
dinogreeves
8月前
dinogreeves
8月前
glenn1919
8月前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
